ArticleCurrent infectious disease reports2012
Enterococcal endocarditis: can we win the war?
Article in Current infectious disease reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01952158 (Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A rabbit model of acute bacteremia and sepsis caused by vancomycin-resistantFrontiers in cellular and infection microbiology · 2026Article
- Isolated Pulmonary Valve Endocarditis Caused byAntibiotics (Basel, Switzerland) · 2025Article
- Enterococcal-host interactions in the gastrointestinal tract and beyond.FEMS microbes · 2024Review
- Enterococcal Endocarditis: Prospective Data from the Iranian Registry of Infective Endocarditis.ARYA atherosclerosis · 2022Article
- Native valve, prosthetic valve, and cardiac device-related infective endocarditis: A review and update on current innovative diagnostic and therapeutic strategies.Frontiers in cell and developmental biology · 2022Review
- Effects of dicopper oxide and copper sulfate on growth performance and gut microbiota in broilers.Poultry science · 2021Article
- Review
- Comparative Microbiome Analysis of Three Species of Laboratory-Reared Periplaneta Cockroaches.The Korean journal of parasitology · 2020Article
- Probiotic Clostridium butyricum Improves the Growth Performance, Immune Function, and Gut Microbiota of Weaning Rex Rabbits.Probiotics and antimicrobial proteins · 2019Article
- Effectiveness of Efflux Pump Inhibitors as Biofilm Disruptors and Resistance Breakers in Gram-Negative (ESKAPEE) Bacteria.Antibiotics (Basel, Switzerland) · 2019Review
- Pathogenicity of Enterococci.Microbiology spectrum · 2019Review
- A Comparison of Three Different Bioinformatics Analyses of the 16S-23S rRNA Encoding Region for Bacterial Identification.Frontiers in microbiology · 2019Article
- Preventing subclinical necrotic enteritis through Lactobacillus johnsonii BS15 by ameliorating lipid metabolism and intestinal microflora in broiler chickens.AMB Express · 2017Article
- Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in anAntimicrobial agents and chemotherapy · 2017Article
- Live ProbioticFrontiers in microbiology · 2017Article
- Article
- Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci.International journal of antimicrobial agents · 2014Review
- What's New in the Treatment of Enterococcal Endocarditis?Current infectious disease reports · 2014Article
- Mechanisms of infective endocarditis: pathogen-host interaction and risk states.Nature reviews. Cardiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Treatment of enterococcal infections has long been recognized as an important clinical challenge, particularly in the setting of infective endocarditis (IE). Furthermore, the increase prevalence of isolates exhibiting multidrug resistance (MDR) to traditional anti-enterococcal antibiotics such as ampicillin, vancomycin and aminoglycosides (high-level resistance) poses immense therapeutic dilemmas in hospitals around the world. Unlike IE caused by most isolates of Enterococcus faecalis, which still retain susceptibility to ampicillin and vancomycin, the emergence and dissemination of a hospital-associated genetic clade of multidrug resistant Enterococcus faecium, markedly limits the therapeutic options. The best treatment of IE MDR enterococcal endocarditis is unknown and the paucity of antibiotics with bactericidal activity against these organisms is a cause of serious concern. Although it appears that we are winning the war against E. faecalis, the battle rages on against isolates of multidrug-resistant E. faecium.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.